Clinical Data Data backs GSK’s ovarian cancer blockbuster hopes PharmaphorumGSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum GSK’s B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme. Clinical DataOncologyRead full story Post navigation Previous: FDA issues complete response letter to Replimune’s RP1 for melanomaNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
